journal article·2025-09-09Open access

Multivalent DNA Origami Enables Single-Molecule Dissection of Integrin αvβ6–Receptor Tyrosine Kinase Crosstalk in Cancer Biology

Tingting Zheng, Lauren Grace Rigby, John F. Marshall, Matteo Palma

ACS Nano· Volume 19· Issue 35

Abstract

Nanoscale organization of integrin-mediated receptor crosstalk is crucial for controlling cellular signaling in cancer biology. Previously, interactions between integrin αvβ6 and receptor tyrosine kinases (RTKs) have been implicated in cancer progression, but the spatial regulatory mechanisms remain undefined. Here, we developed a programmable DNA origami-based platform for nanoscale control of heteroligand multivalency and spacing, enabling systematic investigation of αvβ6-RTK interactions in cancer biology. We identified a spatial activation threshold for the αvβ6-specific peptide A20FMDV2 that promotes A375P β6 cell adhesion and FAK phosphorylation along with spacing- and density-dependent EGFR phosphorylation triggered by EGFR aptamers. Importantly, at an optimized peptide-to-RTK (EGFR, HER2, and Met) aptamer ratio and ligand density, αvβ6-RTK coactivation synergistically enhanced cell spreading and amplified phosphorylation of AKT and ERK, part of the PI3K-AKT and Ras-MAPK pathways. Validation in breast cancer models (MDA-MB-468 and BT-474) highlighted cell-type-specific signaling dependencies. This platform offers a framework for tumor microenvironment mimics and integrin-RTK-targeted therapies, emphasizing the critical role of nanoscale ligand patterning and multivalency in cancer progression.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cell Adhesion Molecules Research · Advanced biosensing and bioanalysis techniques · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Queen Mary University of London, Mile End Road, London E1 4NS, United Kingdom

Barts Cancer Institute, Cancer Research UK Centre of Excellence, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom

Funding

Barts Cancer Institute · China Scholarship Council · Biotechnology and Biological Sciences Research Council

References (64)

Show source-provided references
1. 10.1016/S0092-8674(00)81279-910.1016/S0092-8674(00)81279-9 ↗
2. 10.1016/S0092-8674(02)00971-610.1016/S0092-8674(02)00971-6 ↗
3. 10.1038/nrm149010.1038/nrm1490 ↗
4. 10.1038/nrm390410.1038/nrm3904 ↗
5. 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P ↗
6. 10.1046/j.0022-202x.2001.01379.x10.1046/j.0022-202x.2001.01379.x ↗
7. 10.1007/BF0296718310.1007/BF02967183 ↗
8. 10.1126/sciadv.adk994410.1126/sciadv.adk9944 ↗
9. 10.1073/pnas.08106909810.1073/pnas.081069098 ↗
10. 10.1146/annurev-cellbio-092910-15401710.1146/annurev-cellbio-092910-154017 ↗
11. 10.1002/adhm.20170132410.1002/adhm.201701324 ↗
12. 10.1038/s41467-024-53107-610.1038/s41467-024-53107-6 ↗
13. 10.1021/nl801483w10.1021/nl801483w ↗
14. 10.1021/nl803548b10.1021/nl803548b ↗
15. 10.1038/nature2466210.1038/nature24662 ↗
16. 10.1038/s41563-019-0460-y10.1038/s41563-019-0460-y ↗
17. 10.1529/biophysj.106.08973010.1529/biophysj.106.089730 ↗
18. 10.1021/nl104378f10.1021/nl104378f ↗
19. 10.1021/acs.nanolett.9b0460710.1021/acs.nanolett.9b04607 ↗
20. 10.1126/sciadv.abc164010.1126/sciadv.abc1640 ↗
21. 10.1002/adma.20247016010.1002/adma.202470160 ↗
22. 10.1073/pnas.050940410310.1073/pnas.0509404103 ↗
23. 10.1038/nature0458610.1038/nature04586 ↗
24. 10.1021/acs.accounts.6b0061810.1021/acs.accounts.6b00618 ↗
25. 10.1002/cbic.20190031510.1002/cbic.201900315 ↗
26. 10.1016/j.bpj.2023.10.01310.1016/j.bpj.2023.10.013 ↗
27. 10.1038/nmeth.302510.1038/nmeth.3025 ↗
28. 10.1021/acsnano.8b0801010.1021/acsnano.8b08010 ↗
29. 10.1039/C9FD00023B10.1039/C9FD00023B ↗
30. 10.1038/s41565-020-0719-010.1038/s41565-020-0719-0 ↗
31. 10.1021/jacs.2c1382510.1021/jacs.2c13825 ↗
32. 10.1038/s41557-019-0369-810.1038/s41557-019-0369-8 ↗
33. 10.1038/s41589-024-01572-x10.1038/s41589-024-01572-x ↗
34. 10.1021/acs.nanolett.2c0027510.1021/acs.nanolett.2c00275 ↗
35. 10.1002/smll.20210167810.1002/smll.202101678 ↗
36. 10.1002/adma.20250057710.1002/adma.202500577 ↗
37. 10.1002/smll.20250354310.1002/smll.202503543 ↗
38. 10.1021/acs.nanolett.3c0427210.1021/acs.nanolett.3c04272 ↗
39. 10.1093/nar/gkaa27410.1093/nar/gkaa274 ↗
40. 10.1021/acsnano.2c1264710.1021/acsnano.2c12647 ↗
41. 10.1021/acsnano.2c0627510.1021/acsnano.2c06275 ↗
42. 10.1021/acs.nanolett.2c0248910.1021/acs.nanolett.2c02489 ↗
43. 10.1038/s41563-024-01865-510.1038/s41563-024-01865-5 ↗
44. 10.1038/s41565-023-01507-y10.1038/s41565-023-01507-y ↗
45. 10.1038/s41467-023-44059-410.1038/s41467-023-44059-4 ↗
46. 10.1073/pnas.210905711810.1073/pnas.2109057118 ↗
47. 10.1021/acsnano.0c1063210.1021/acsnano.0c10632 ↗
48. 10.1038/s41467-022-31684-810.1038/s41467-022-31684-8 ↗
49. 10.1126/sciadv.add110610.1126/sciadv.add1106 ↗
50. 10.1038/s41565-023-01471-710.1038/s41565-023-01471-7 ↗
51. 10.1002/path.274510.1002/path.2745 ↗
52. 10.1016/j.bbrc.2014.09.02310.1016/j.bbrc.2014.09.023 ↗
53. 10.1073/pnas.130259411010.1073/pnas.1302594110 ↗
54. 10.1039/C4CC06016D10.1039/C4CC06016D ↗
55. 10.1038/ncb327710.1038/ncb3277 ↗
56. 10.1016/j.cell.2010.06.01110.1016/j.cell.2010.06.011 ↗
57. 10.1038/cr.2014.8910.1038/cr.2014.89 ↗
58. 10.1021/acsnano.2c1174410.1021/acsnano.2c11744 ↗
59. 10.3390/cancers1203073110.3390/cancers12030731 ↗
60. Thomas, J. R.; Moore, K. M.; Sproat, C.; Maldonado-Lorca, H. J.; Mo, S.; Haider, S.; Hammond, D.; Thomas, G. J.; Prior, I. A.; Cutillas, P. R.; Jones, L. J.; Marshall, J. F.; Morgan, M. R. Integrin αVβ6-EGFR Crosstalk Regulates Bidirectional Force Transmission and Controls Breast Cancer Invasion bioRxiv 2018407908.
61. 10.1242/jcs.23884010.1242/jcs.238840 ↗
62. 10.1016/j.celrep.2018.02.03110.1016/j.celrep.2018.02.031 ↗
63. 10.1021/nn506014s10.1021/nn506014s ↗
64. 10.1039/D4MA00828F10.1039/D4MA00828F ↗